Riskpilot← Back to searchSign inGet full accessPHARMAKNOWLEDGE ApS
APSActiveCVR 30523202Bakkevej 6Computer consultancy and computer facilities management activities · NACE 6220Est. 2008— employees
Revenue 2024
DKK -5K
+9% vs 2023
EBITDA margin
100.0%
-9% vs 2023
Equity ratio
98.9%
Financial strength
Net profit 2024
DKK 48K
+26% vs 2023
| Revenue | DKK -5K | +9% |
| EBITDA | DKK -5K | -9% |
| Net profit | DKK 48K | +26% |
| Total assets | DKK 532K | +11% |
| Equity | DKK 526K | +10% |
| Employees | — | — |
Legal name
PHARMAKNOWLEDGE ApS
CVR number
30523202
Legal form
Anpartsselskab
NACE code
6220 · Computer consultancy and computer facilities management activities
Founded
1. september 2008
Share capital
DKK 125.000
Employees
—
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af selskabets direktør, der på selskabets ordinære generalforsamling vælges for 1 år af gangen.
Company purpose
Selskabets formål er at yde rådgivning til Pharma og Biotek virksomheder.
Address
Bakkevej 6
Phone
+4544448367
Email
lene.worsaae@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -17 | -2 | -1 | -3 | -4 | -4 | -4 | -4 | -4 | 23 | -4 | -5 | -5 |
| Staff expenses | -1 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -18 | -2 | -1 | -3 | -4 | -4 | -4 | -4 | -4 | 23 | -4 | -5 | -5 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -18 | -2 | -1 | -3 | -4 | -4 | -4 | -4 | -4 | 23 | -4 | -5 | -5 |
| Net financials | 2 | 1 | 1 | -4 | 31 | 26 | -12 | 59 | 27 | 50 | -74 | 52 | 66 |
| Profit before tax | -16 | -1 | -1 | -6 | 28 | 22 | -17 | 56 | 23 | 72 | -78 | 47 | 61 |
| Tax | -2 | 1 | 2 | 2 | 6 | 5 | -4 | 12 | 5 | 16 | -16 | 10 | 13 |
| Net profit | -14 | -2 | -3 | -8 | 22 | 17 | -13 | 43 | 18 | 56 | -61 | 38 | 48 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 626 | 520 | 418 | 410 | 431 | 449 | 436 | 479 | 499 | 509 | 443 | 480 | 532 |
| Equity | 617 | 518 | 417 | 409 | 430 | 447 | 434 | 478 | 496 | 502 | 441 | 478 | 526 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 9 | 2 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 7 | 3 | 1 | 6 |
| Total debt | 9 | 2 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 7 | 3 | 1 | 6 |
EBITDA margin
-516100.0%
This company
15.8%
Market median
-3266556% vs market
20122024
Equity ratio
98.9%
This company
38.2%
Market median
+159% vs market
20122024
Return on equity
9.0%
This company
18.4%
Market median
-51% vs market
20122024
Net profit margin
4755400.0%
This company
8.1%
Market median
+58708542% vs market
20122024
Asset turnover
-0.01×
This company
1.12×
Market median
-101% vs market
20122024
Debt / equity
0.01×
This company
0.62×
Market median
+98% vs market
20122024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
No data on file.
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100.0% | 100.0% | 2008 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of PHARMAKNOWLEDGE ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|